VectivBio Holding AG Price & Performance (VECT)

Ironwood Pharmaceuticals has initiated a rolling New Drug Application for apraglutide in adults dependent on parenteral support due to short bowel syndrome. This follows positive results from its pivotal Phase III trial. The company is also conducting an extension study and plans further regulatory filings, while prioritizing its GI-focused strategy.12

Shares of VectivBio Holding AG have climbed to $16.85, marking a 186% increase year-over-year. The company’s momentum follows successful clinical development of apraglutide for rare gastrointestinal conditions, with analysts maintaining a consensus 'Hold' rating and a target price of $18.33, indicating cautious optimism for future growth.34

VectivBio’s robust funding and recent clinical milestones, including positive results for apraglutide in short bowel syndrome, have positioned it as a leader in rare disease therapeutics. Strategic licensing agreements and ongoing studies underscore its commitment to innovation, with investors closely watching for further regulatory and commercial developments.25